Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OVRAL vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
OVRAL is a combination oral contraceptive containing ethinyl estradiol and norgestrel. It inhibits ovulation by suppressing gonadotropin-releasing hormone (Gn RH) secretion from the hypothalamus, reducing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) release from the pituitary. Additionally, it increases cervical mucus viscosity and alters endometrial receptivity, impeding sperm penetration and implantation.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Prevention of pregnancy,Treatment of moderate acne vulgaris in females at least 15 years of age who have achieved menarche and are unresponsive to topical therapies
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet (norgestrel 0.3 mg with ethinyl estradiol 0.03 mg) orally once daily for 21 days followed by 7 days of placebo.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Norgestrel: 24–32 hours; Ethinyl estradiol: 12–18 hours; steady-state achieved after 5–7 days
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Ethinyl estradiol is primarily metabolized by CYP3A4, with sulfation and glucuronidation pathways. Norgestrel is hydroxylated via CYP3A4 and undergoes reduction and conjugation.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Renal (60% as metabolites, ~40% unchanged); biliary/fecal (40%)
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Norgestrel: 93–97% bound to SHBG; Ethinyl estradiol: 97–98% bound to albumin and SHBG
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Norgestrel: 1.5–2.5 L/kg; Ethinyl estradiol: 2.5–4.0 L/kg; extensive tissue distribution
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Norgestrel: ~90%; Ethinyl estradiol: ~45–50% due to first-pass metabolism
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No specific dose adjustment is required for mild to moderate renal impairment. Use with caution in severe renal impairment or end-stage renal disease due to potential for hormonal accumulation and adverse effects.
No data available for fictional drug ALYACEN 777.
Contraindicated in patients with acute or chronic hepatic disease or history of hepatic tumors (benign or malignant). In Child-Pugh class A (mild impairment), use with caution; in Child-Pugh class B or C (moderate to severe impairment), contraindicated.
No data available for fictional drug ALYACEN 777.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults: one tablet orally daily for 21 days followed by 7 days of placebo.
No data available for fictional drug ALYACEN 777.
Not indicated for use in postmenopausal women. No specific geriatric dosing adjustments; consider increased risk of thrombosis and cardiovascular events in older women of reproductive age.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age and with the number of cigarettes smoked, and is particularly marked in women over 35 years of age. Women who use combination oral contraceptives should be strongly advised not to smoke.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Thrombotic disorders: venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction,Hepatic neoplasia: liver tumors (benign and malignant),Cervical cancer: increased risk with long-term use,Hypertension,Gallbladder disease,Carbohydrate and lipid metabolic effects,Headache (including migraine),Bleeding irregularities (breakthrough bleeding, spotting, amenorrhea),Depression,Ocular lesions (e.g., retinal thrombosis),Contact lens intolerance
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Known or suspected pregnancy,Current or past history of thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast cancer or other estrogen-sensitive neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Major surgery with prolonged immobilization,Heavy smoking (≥15 cigarettes/day) in women over 35 years of age,Known hypertriglyceridemia,Hypersensitivity to any component
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
Avoid grapefruit juice as it may increase estrogen levels and side effect risk. St. John's wort (herbal supplement) reduces contraceptive efficacy by inducing CYP3A4. No specific food restrictions; maintain consistent intake to minimize GI upset.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
FDA Pregnancy Category X. First trimester: Known teratogen; associated with cardiovascular defects, neural tube defects, and limb reduction defects. Second trimester: Risk of fetal masculinization with progestins. Third trimester: Potential for feminization of male fetuses and virilization of female fetuses; increased risk of fetal adrenal suppression.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Contraindicated during breastfeeding. M/P ratio not established. Estrogens and progestins are excreted in human milk and may reduce milk production and quality. Potential adverse effects on infant include jaundice, breast enlargement, and hormonal disruption.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
Contraindicated in pregnancy; no dose adjustments applicable as use is contraindicated.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
Ovral (norgestrel/ethinyl estradiol) is a combined oral contraceptive with high progestin potency, increasing the risk of venous thromboembolism. Consider for patients needing reliable contraception but avoid in those with migraine with aura, history of thromboembolic disorders, or liver disease. Breakthrough bleeding is common; manage by adjusting pill schedule or switching to a higher estrogen dose. Drug interactions with cytochrome P-450 inducers (e.g., rifampin, anticonvulsants) may reduce efficacy; consider backup contraception.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one tablet at the same time daily; missed pills require backup contraception.,Common side effects include nausea, headache, and breast tenderness; these often improve after a few cycles.,Report symptoms of thromboembolism (leg pain/swelling, sudden chest pain or dyspnea) or stroke (severe headache, vision changes).,Do not smoke while on Ovral; smoking increases risk of serious cardiovascular side effects, especially if over 35 years old.,Antibiotics (except rifampin) do not reduce efficacy; but certain anticonvulsants and St. John's wort do; use backup method with these.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OVRAL vs ALYACEN 777, answered by our medical review team.
OVRAL is a Oral Contraceptive that works by OVRAL is a combination oral contraceptive containing ethinyl estradiol and norgestrel. It inhibits ovulation by suppressing gonadotropin-releasing hormone (Gn RH) secretion from the hypothalamus, reducing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) release from the pituitary. Additionally, it increases cervical mucus viscosity and alters endometrial receptivity, impeding sperm penetration and implantation.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OVRAL and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OVRAL is: One tablet (norgestrel 0.3 mg with ethinyl estradiol 0.03 mg) orally once daily for 21 days followed by 7 days of placebo.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OVRAL and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OVRAL is classified as Category C. FDA Pregnancy Category X. First trimester: Known teratogen; associated with cardiovascular defects, neural tube defects, and limb reduction defects. Second trimester: Risk of fetal. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.